Back to Sectors

AVXL

ANAVEX LIFE SCIENCES CORP.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

BEARISH | 80% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeBEARISH | 80% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeBEARISH | 80% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeBEARISH | 80% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeBEARISH | 80% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeBEARISH | 80% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeBEARISH | 80% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 22

Nasdaq delinquency notice due to failure to file periodic financial reports.

regulatory action
80%
neutralMay 22

Management focus shifting toward regulatory remediation and compliance planning.

management change
30%
bearishMay 22

Nasdaq delinquency notice due to failure to file periodic financial reports.

regulatory action
80%
neutralMay 22

Management focus shifting toward regulatory remediation and compliance planning.

management change
30%
bearishMay 22

Nasdaq delinquency notice due to failure to file periodic financial reports.

regulatory action
80%
neutralMay 22

Management focus shifting toward regulatory remediation and compliance planning.

management change
30%
bearishMay 22

Nasdaq delinquency notice due to failure to file periodic financial reports.

regulatory action
80%
neutralMay 22

Management focus shifting toward regulatory remediation and compliance planning.

management change
30%
bearishMay 22

Nasdaq delinquency notice due to failure to file periodic financial reports.

regulatory action
80%
neutralMay 22

Management focus shifting toward regulatory remediation and compliance planning.

management change
30%
bearishMay 22

Nasdaq delinquency notice due to failure to file periodic financial reports.

regulatory action
80%
neutralMay 22

Management focus shifting toward regulatory remediation and compliance planning.

management change
30%
bearishMay 22

Nasdaq delinquency notice due to failure to file periodic financial reports.

regulatory action
80%
neutralMay 22

Management focus shifting toward regulatory remediation and compliance planning.

management change
30%

Filing History

8-KMay 22, 2026

Anavex Life Sciences is currently navigating a critical compliance gap after failing to file its Q1 2026 Form 10-Q, leading to a formal delinquency notice from Nasdaq. While the company remains listed and has until July 20 to submit a compliance plan, the event highlights a tension between its aggressive clinical ambitions and its operational discipline. The market must now weigh whether this is a mere administrative lapse or a symptom of a cash-starved operation. The eventual filing of the 10-Q will be the primary catalyst, as it will reveal the actual state of the company's balance sheet and its ability to fund ongoing trials.